NCT04666038 2026-04-24BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT07052695 2025-12-15Mosunetuzumab for CLL MRD ClearanceDana-Farber Cancer InstitutePhase 1/2 Recruiting40 enrolled